Michelle C Starr1, Irene J Chang2, Laura S Finn3, Angela Sun4, Austin A Larson5, Jens Goebel6, Coral Hanevold7, Jenny Thies4, Johan L K Van Hove5, Sangeeta R Hingorani7, Christina Lam4. 1. Department of Pediatrics, Division of Nephrology, Seattle Children's Hospital and University of Washington, 4800 Sand Point Way NE, OC.9.830, Seattle, WA, 98105, USA. michelle.starr@seattlechildrens.org. 2. Department of Medical Genetics, University of Washington Medical Center, Seattle, WA, USA. 3. Department of Pathology, Seattle Children's Hospital and University of Washington, Seattle, WA, USA. 4. Department of Pediatrics, Division of Genetic Medicine, Seattle Children's Hospital and University of Washington, Seattle, WA, USA. 5. Department of Pediatrics, Section of Clinical Genetics and Metabolism, University of Colorado, Aurora, CO, USA. 6. Department of Pediatrics, Section of Nephrology, University of Colorado, Aurora, CO, USA. 7. Department of Pediatrics, Division of Nephrology, Seattle Children's Hospital and University of Washington, 4800 Sand Point Way NE, OC.9.830, Seattle, WA, 98105, USA.
Abstract
BACKGROUND: Nephrotic syndrome can be caused by a subgroup of mitochondrial diseases classified as primary coenzyme Q10 (CoQ10) deficiency. Pathogenic COQ2 variants are a cause of primary CoQ10 deficiency and present with phenotypes ranging from isolated nephrotic syndrome to fatal multisystem disease. CASE-DIAGNOSIS/TREATMENT: We report three pediatric patients with COQ2 variants presenting with nephrotic syndrome. Two of these patients had normal leukocyte CoQ10 levels prior to treatment. Pathologic findings varied from mesangial sclerosis to focal segmental glomerulosclerosis, with all patients having abnormal appearing mitochondria on kidney biopsy. In two of the three patients treated with CoQ10 supplementation, the nephrotic syndrome resolved; and at follow-up, both have normal renal function and stable proteinuria. CONCLUSIONS: COQ2 nephropathy should be suspected in patients presenting with nephrotic syndrome, although less common than disease due to mutations in NPHS1, NPHS2, and WT1. The index of suspicion should remain high, and we suggest that providers consider genetic evaluation even in patients with normal leukocyte CoQ10 levels, as levels may be within normal range even with significant clinical disease. Early molecular diagnosis and specific treatment are essential in the management of this severe yet treatable condition.
BACKGROUND:Nephrotic syndrome can be caused by a subgroup of mitochondrial diseases classified as primary coenzyme Q10 (CoQ10) deficiency. Pathogenic COQ2 variants are a cause of primary CoQ10 deficiency and present with phenotypes ranging from isolated nephrotic syndrome to fatal multisystem disease. CASE-DIAGNOSIS/TREATMENT: We report three pediatric patients with COQ2 variants presenting with nephrotic syndrome. Two of these patients had normal leukocyte CoQ10 levels prior to treatment. Pathologic findings varied from mesangial sclerosis to focal segmental glomerulosclerosis, with all patients having abnormal appearing mitochondria on kidney biopsy. In two of the three patients treated with CoQ10 supplementation, the nephrotic syndrome resolved; and at follow-up, both have normal renal function and stable proteinuria. CONCLUSIONS:COQ2nephropathy should be suspected in patients presenting with nephrotic syndrome, although less common than disease due to mutations in NPHS1, NPHS2, and WT1. The index of suspicion should remain high, and we suggest that providers consider genetic evaluation even in patients with normal leukocyte CoQ10 levels, as levels may be within normal range even with significant clinical disease. Early molecular diagnosis and specific treatment are essential in the management of this severe yet treatable condition.
Authors: Francesca Diomedi-Camassei; Silvia Di Giandomenico; Filippo M Santorelli; Gianluca Caridi; Fiorella Piemonte; Giovanni Montini; Gian Marco Ghiggeri; Luisa Murer; Laura Barisoni; Anna Pastore; Andrea Onetti Muda; Maria Luisa Valente; Enrico Bertini; Francesco Emma Journal: J Am Soc Nephrol Date: 2007-09-12 Impact factor: 10.121
Authors: Maria Andrea Desbats; Annalisa Vetro; Ivan Limongelli; Giada Lunardi; Alberto Casarin; Mara Doimo; Marco Spinazzi; Corrado Angelini; Giovanna Cenacchi; Alberto Burlina; Maria Angeles Rodriguez Hernandez; Lino Chiandetti; Maurizio Clementi; Eva Trevisson; Placido Navas; Orsetta Zuffardi; Leonardo Salviati Journal: Eur J Hum Genet Date: 2015-01-07 Impact factor: 4.246
Authors: Neringa Jurkute; Francesca Cancellieri; Lisa Pohl; Catherina H Z Li; Robert A Heaton; Janine Reurink; James Bellingham; Mathieu Quinodoz; Georgia Yioti; Maria Stefaniotou; Marianna Weener; Theresia Zuleger; Tobias B Haack; Katarina Stingl; Carel B Hoyng; Omar A Mahroo; Iain Hargreaves; F Lucy Raymond; Michel Michaelides; Carlo Rivolta; Susanne Kohl; Susanne Roosing; Andrew R Webster; Gavin Arno Journal: NPJ Genom Med Date: 2022-10-20 Impact factor: 6.083
Authors: Aliaa H Abdelhakim; Avinash V Dharmadhikari; Sara D Ragi; Jose Ronaldo Lima de Carvalho; Christine L Xu; Amanda L Thomas; Christie M Buchovecky; Mahesh M Mansukhani; Ali B Naini; Jun Liao; Vaidehi Jobanputra; Irene H Maumenee; Stephen H Tsang Journal: Orphanet J Rare Dis Date: 2020-11-13 Impact factor: 4.123